Open AccessCost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
Author(s) -
Marzieh Nosrati,
Nikinaz Ashrafi Shahmirzadi,
Mohammad H. Afzali,
Pardis Zaboli,
Hasti Rouhani,
Haleh Hamedifar,
Mirhamed Hajimiri
Publication year - 2020
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_1166_19
Subject(s) - bosentan , medicine , cardiology , liberian dollar , intensive care medicine , endothelin receptor , finance , receptor , economics
Endothelin (ET) receptor antagonists (ERAs) have considerable improvements in pulmonary arterial hypertension (PAH) patients' symptoms. Macitentan, a novel ERA, has more significant positive effects like reduction of morbidity and mortality in PAH patients by 45% and decreases PAH hospitalization. Besides, macitentan was able to improve both the physical and mental aspects of patients' lives. This study aimed to evaluate an incremental cost-utility analysis of macitentan compared with bosentan in PAH patients in the Iranian health care system.